Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
read more
Abstract: The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer. Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths. Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar. Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment. A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake. Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Global cancer transitions according to the Human Development Index (2008-2030): a population-based study
TL;DR: The findings suggest that rapid societal and economic transition in many countries means that any reductions in infection-related cancers are offset by an increasing number of new cases that are more associated with reproductive, dietary, and hormonal factors.
2.2K
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal-Hanjani,Gareth A. Wilson,Nicholas McGranahan,Nicolai Juul Birkbak,Thomas B.K. Watkins,Selvaraju Veeriah,Seema Shafi,Diana Johnson,Richard Mitter,Rachel Rosenthal,Max Salm,Stuart Horswell,Mickael Escudero,Nik Matthews,Andrew Rowan,Tim Chambers,David A. Moore,Samra Turajlic,Hang Xu,Siow Ming Lee,Martin Forster,Tanya Ahmad,Crispin T. Hiley,Christopher Abbosh,Mary Falzon,Elaine Borg,Teresa Marafioti,David Lawrence,Martin Hayward,Shyam Kolvekar,Nikolaos Panagiotopoulos,Sam M. Janes,Ricky Thakrar,Asia Ahmed,Fiona H Blackhall,Yvonne Summers,Rajesh Shah,Leena Dennis Joseph,Anne Marie Quinn,Phil Crosbie,Babu Naidu,Gary Middleton,Gerald Langman,Simon Trotter,Marianne Nicolson,Hardy Remmen,Keith Kerr,Mahendran Chetty,Lesley Gomersall,Dean A. Fennell,Apostolos Nakas,Sridhar Rathinam,Girija Anand,Sajid A. Khan,Peter Russell,Veni Ezhil,Babikir Ismail,Melanie Irvin-Sellers,Vineet Prakash,Jason F. Lester,Malgorzata Kornaszewska,Richard Attanoos,Haydn Adams,Helen Davies,Stefan C. Dentro,Philippe Taniere,Brendan O'Sullivan,Helen Lowe,John A. Hartley,Natasha Iles,Harriet Bell,Yenting Ngai,Jacqui Shaw,Javier Herrero,Zoltan Szallasi,Roland F. Schwarz,Aengus Stewart,Sergio A. Quezada,John Le Quesne,Peter Van Loo,Caroline Dive,Allan Hackshaw,Charles Swanton +82 more
TL;DR: Intratumor heterogeneity mediated through chromosome instability was associated with an increased risk of recurrence or death, a finding that supports the potential value of chromosome instability as a prognostic predictor.
Renal cell carcinoma.
James J. Hsieh,Mark P. Purdue,Sabina Signoretti,Charles Swanton,Laurence Albiges,Manuela Schmidinger,Daniel Y. Heng,James Larkin,Vincenzo Ficarra +8 more
- 09 Mar 2017
TL;DR: An overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy are provided.
Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors
Fatima Haggar,Robin P. Boushey +1 more
TL;DR: The incidence, mortality, and survival rates for colorectal cancer are reviewed, with attention paid to regional variations and changes over time.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
2K
References
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
22.9K
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
TL;DR: This timely monograph is a distillation of knowledge of hepatitis B, C and D, based on a review of 1000 studies by a small group of scientists, and it is concluded that hepatitis D virus cannot be classified as a human carcinogen.
11.5K
•Book
International Classification of Diseases for Oncology
Constance L. Percy,Valerie Van Holten,Calum S. Muir +2 more
- 01 Jun 1990
TL;DR: This list of diseases for oncology includes cancers of the central nervous system, as well as other types of diseases such as lymphoma, leukaemia, and so on.
4.2K
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
International Classification of Diseases for Oncology
TL;DR: Use ofImmunofluorescence in the Diagnosis of Virus Infections using audio-tape slide programme and slides and cassette by P. S. Gardner.
3.5K